Myocardial viability and long-term outcomes in ischemic cardiomyopathy

Julio A. Panza; Eric J. Velazquez; Robert O. Bonow

doi:10.1056/NEJMc1913972

Myocardial viability and long-term outcomes in ischemic cardiomyopathy

Julio A. Panza^*, Eric J. Velazquez, Robert O. Bonow

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	2373-2374
Number of pages	2
Journal	New England Journal of Medicine
Volume	381
Issue number	24
DOIs	https://doi.org/10.1056/NEJMc1913972
State	Published - Dec 12 2019

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJMc1913972

Cite this

@article{08c81b03ec3b4df2a8d399e776411708,

title = "Myocardial viability and long-term outcomes in ischemic cardiomyopathy",

author = "Panza, {Julio A.} and Velazquez, {Eric J.} and Bonow, {Robert O.}",

note = "Funding Information: Dr. Bengel reports receiving institutional research grant support from Siemens Healthineers. No other potential conflict of interest relevant to this letter was reported. Funding Information: Dr. Sharma reports receiving grant support from Novartis, Endologix, Tasly, and Perfuse Therapeutics, speaking fees from Novartis, and consulting fees from Endologix. No other potential conflict of interest relevant to this letter was reported.",

year = "2019",

month = dec,

day = "12",

doi = "10.1056/NEJMc1913972",

language = "English (US)",

volume = "381",

pages = "2373--2374",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "24",

}

TY - JOUR

T1 - Myocardial viability and long-term outcomes in ischemic cardiomyopathy

AU - Panza, Julio A.

AU - Velazquez, Eric J.

AU - Bonow, Robert O.

N1 - Funding Information: Dr. Bengel reports receiving institutional research grant support from Siemens Healthineers. No other potential conflict of interest relevant to this letter was reported. Funding Information: Dr. Sharma reports receiving grant support from Novartis, Endologix, Tasly, and Perfuse Therapeutics, speaking fees from Novartis, and consulting fees from Endologix. No other potential conflict of interest relevant to this letter was reported.

PY - 2019/12/12

Y1 - 2019/12/12

UR - http://www.scopus.com/inward/record.url?scp=85076435158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076435158&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1913972

DO - 10.1056/NEJMc1913972

M3 - Letter

C2 - 31826352

AN - SCOPUS:85076435158

SN - 0028-4793

VL - 381

SP - 2373

EP - 2374

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 24

ER -

Myocardial viability and long-term outcomes in ischemic cardiomyopathy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this